Research Library
Survodutide research
7 articles to explore, with links to 9 original sources.
About Survodutide
Survodutide is a peptide analogue used in research on glucagon and GLP-1 receptor signaling.
Understand the science
How SYNCHRONIZE-1 counted average weight change and response rates
Survodutide is an investigational peptide that activates GLP-1 and glucagon receptors. SYNCHRONIZE-1 tested it in adults with obesity or overweight and a related complication who did not have diabetes.
1 source (2026)
Explore study findings
What the survodutide cardiovascular trial was designed to count
Survodutide is an investigational peptide that activates the glucagon and GLP-1 receptors. The SYNCHRONIZE cardiovascular study was designed to examine whether cardiovascular events occurred at different rates in adults with excess body weight assigned to survodutide or placebo.
2 sources (2023, 2026)
Why the two LIVERAGE studies use different liver outcomes
Survodutide is an investigational peptide that acts on the glucagon and GLP-1 receptors. The LIVERAGE registry records describe two trials that ask different questions about liver disease at different stages of scarring.
3 sources (2024, 2026)
What the Chinese and Japanese trials tell us about who was studied
Survodutide is an investigational peptide that acts at glucagon and GLP-1 receptors. Two 2026 design reports described how researchers set up randomized weight-management trials in China and Japan, including who could enroll and when outcomes would be measured.
2 sources (2026)
What an MRI showed about liver fat in SYNCHRONIZE-MASLD
Survodutide is an investigational glucagon and GLP-1 receptor agonist peptide. A phase 3 study reported in 2026 asked whether it changed liver fat and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD.
2 sources (2024, 2026)
Why the earlier MASH trial examined liver tissue directly
Survodutide is an investigational peptide with activity at the glucagon and GLP-1 receptors. The older direct study for the biopsy question was a phase 2 trial in adults with confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and varying degrees of scarring.
2 sources (2024, 2026)
Check methods and identity
How SYNCHRONIZE-2 measured weight in adults with type 2 diabetes
Survodutide is an investigational peptide that activates the glucagon receptor and the GLP-1 receptor. The phase 3 SYNCHRONIZE-2 trial asked what happened to body weight in adults with type 2 diabetes and excess body weight who were assigned to survodutide or placebo.
2 sources (2026)
